Compare · CSTL vs HUM
CSTL vs HUM
Side-by-side comparison of Castle Biosciences Inc. (CSTL) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CSTL and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $51.90B, about 50.3x CSTL ($1.03B).
- Over the past year, CSTL is up 41.9% and HUM is up 54.8% - HUM leads by 12.9 points.
- HUM has been more active in the news (13 items in the past 4 weeks vs 12 for CSTL).
- HUM has more recent analyst coverage (25 ratings vs 6 for CSTL).
- Company
- Castle Biosciences Inc.
- Humana Inc.
- Price
- -
- -
- Market cap
- $1.03B
- $51.90B
- 1M return
- -13.25%
- +7.44%
- 1Y return
- +41.91%
- +54.83%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 12
- 13
- Recent ratings
- 6
- 25
Castle Biosciences Inc.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest CSTL
- Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026
- SEC Form 4 filed by Castle Biosciences Inc.
- ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus
- SEC Form 4 filed by Castle Biosciences Inc.
- SEC Form 144 filed by Castle Biosciences Inc.
- SEC Form 4 filed by Castle Biosciences Inc.
- Chief Commercial Officer Juvenal Tobin W sold $232,128 worth of shares (6,577 units at $35.29) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 52,007 units (SEC Form 4)
- Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management
- New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus
- New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™
Latest HUM
- Humana Announces New Strategic Joint Venture with BlackRock to Manage CenterWell Senior Primary Care Clinics
- SEC Form 8-K filed by Humana Inc.
- Humana Inc. to Release Third Quarter 2026 Results on November 6, 2026
- Humana upgraded by Raymond James with a new price target
- After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports
- Humana upgraded by Robert W. Baird with a new price target
- Humana Announces Improved CMS Star Ratings with 95 Percent of Medicare Advantage Members in 4-Star or Above Plans for 2027
- SEC Form 8-K filed by Humana Inc.
- Humana upgraded by Cantor Fitzgerald with a new price target
- Humana Generates Nearly $20 Billion in Economic Impact Across Kentucky, New Report Finds